
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
The author discusses how x-ray spectrometry can be an effective way to measure these impurities and meet regulatory guidelines.
from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.
View other articles in the
over 10 years ago
Optimizing Tablet Compressionover 10 years ago
Excipient Quality and Selectionover 10 years ago
Filling the Analysis Gap in the Move to Continuous Processingover 10 years ago
Modeling and Simulation Move Downstreamover 10 years ago
Unifying Excipient Databasesover 10 years ago
Establishing a New Performance Standard for HPMC Capsules





